ClinicalTrials.gg
RecruitingNCT07666412Updated Nov 12, 2026

Assessment of Ovarian Reserve in the Treatment of Ovarian Endometrioma With Cystectomy or Argon Plasma Coagulation

An interventional study of Argon Plasma Coagulation (APC) ablation in Ovarian Endometrioma, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Endometriosis by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 8 open to participants now, 9 under way, none of them phase 3. Endometriosis · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Started
2026
the only one that year
No phase
7 of 21
1 open now
Registered
21st of 21
by date

Among the 21 studies in Endometriosis by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is the only one that started in 2026, is one of 7 with no phase, and was the 21st registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

8 of the 21 studies in Endometriosis by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Endometriosis by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

Endometriosis is a benign, chronic, and often recurrent gynecological disease affecting approximately 10% of women of reproductive age. Among the different manifestations of the disease, ovarian endometrioma represents one of the most common forms, occurring in up to 50% of affected patients. Endometriomas may cause progressive damage to ovarian tissue through both mechanical effects and direct toxic effects related to the inflammatory and oxidative content of the cyst, ultimately leading to a reduction in ovarian reserve.

When medical treatment is insufficient or not indicated, surgery represents a therapeutic option. The aim of surgery is to remove the cyst while minimizing the risk of recurrence and preserving as much healthy ovarian tissue as possible. Currently, the most widely used surgical technique is laparoscopic cystectomy performed by stripping the cyst capsule. However, this procedure may result in the inadvertent removal of healthy ovarian tissue and a consequent reduction in ovarian reserve.

In recent years, ablative surgical techniques have been developed with the aim of reducing damage to the ovarian parenchyma. Among these, Argon Plasma Coagulation (APC) is a technique that uses a high-energy argon plasma jet to vaporize and coagulate superficial tissues. From a histological perspective, APC induces limited-depth tissue necrosis, generally confined to the cyst capsule, potentially reducing the risk of damage to the underlying ovarian tissue. In addition, this technology may offer practical and economic advantages.

Several studies suggest that ablative techniques may have a lower impact on ovarian reserve compared with cystectomy, as assessed by antral follicle count and serum anti-Müllerian hormone (AMH) levels, a reliable biomarker of ovarian reserve. However, the available evidence mainly derives from observational studies or studies using ablative technologies different from the one investigated in the present study. Furthermore, the systematic use of ablative techniques remains controversial in clinical practice, partly because of the potential risk of recurrence associated with residual endometriotic tissue.

To date, no randomized clinical trials have directly compared the impact of APC versus cystectomy on ovarian reserve in patients with ovarian endometrioma. Moreover, data are lacking regarding recurrence risk, post-treatment ovarian ultrasound characteristics following APC ablation, and the histological effects of this technique on endometriotic cysts.

In light of these considerations, the present randomized clinical trial aims to compare the effect of cystectomy and Argon Plasma Coagulation ablation on the preservation of ovarian reserve in patients undergoing surgical treatment for ovarian endometrioma, while also evaluating ultrasound outcomes and recurrence risk during follow-up.

03

Conditions studied

  • Ovarian Endometrioma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic patients (pain and/or infertility) affected by ovarian endometriomas (unilateral or bilateral).
  • Age between 18 and 40 years.
  • Ultrasound diagnosis of one or more mono- or bilateral endometriotic cysts, with a maximum overall diameter (per ovary) ≤ 80 mm and at least one cyst diameter ≥ 20 mm.
  • Use of hormonal therapy for at least 1 month prior to surgery.
  • Willingness to undergo follow-up at 40-60 days and 12 months, according to clinical practice.
  • Willingness to receive postoperative hormonal therapy, according to clinical practice, to minimize the risk of recurrence.
  • Written obtained.

Exclusion criteria

Exclusion Criteria:

  • History of unilateral ovariectomy/adnexectomy or hysterectomy.
  • Ultrasound evidence of other non-endometriotic ovarian cysts requiring surgical removal.
  • Atypical endometrioma or ultrasound suspicion of .
  • Previous surgery on one or both ovaries within 12 months prior to surgery.
  • Known or suspected active oncological disease.
  • Inability to undergo transvaginal ultrasound examination (patients with intact hymen).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Argon Plasma Coagulation (APC) ablation

    Cyst opening and drainage, ablation of the inner surface of the cyst capsule using APC, and multiple biopsies of the cyst capsule.

    Procedure: Argon Plasma Coagulation (APC) ablation

  • No intervention
    Cystectomy

    Removal of the cyst capsule using the stripping technique, followed by ultra-selective hemostasis with bipolar energy and suturing of the ovarian parenchyma for hemostatic and reconstructive purposes (when indicated).

Interventions

  • ProcedureArgon Plasma Coagulation (APC) ablation

    Cyst opening and drainage, ablation of the inner surface of the cyst capsule using APC, and multiple biopsies of the cyst capsule.

06

What researchers measure

Primary outcomes

  1. Late effects of APC or cystectomy on the AFC of the treated ovary

    Change in antral follicle count (ΔAFC) of the treated ovary between baseline (T0) and 12 months (T2).

    Time frame: 12 months after surgery (T2).

Secondary outcomes

  1. Early effects of APC or cystectomy on the AFC of the treated ovary

    Change in antral follicle count (ΔAFC) of the treated ovary between baseline (T0) and 40-60 days after surgery (T1).

    Time frame: 40-60 days after surgery (T1).

  2. Late effects of APC or cystectomy on serum AMH levels

    Change in serum AMH levels (ΔAMH) between baseline (T0) and 12 months (T2).

    Time frame: 12 months after surgery (T2).

  3. Early effects of APC or cystectomy on serum AMH levels

    Change in serum AMH levels (ΔAMH) between baseline (T0) and 40-60 days after surgery (T1).

    Time frame: 40-60 days after surgery (T1).

  4. Temporal pattern of AFC variation

    Antral follicle count (AFC) values of the ovary treated with APC and cystectomy

    Time frame: Baseline (T0), 40-60 days after surgery (T1), 12 months after surgery (T2)

  5. Temporal pattern of AMH variation

    Serum AMH levels in patients undergoing APC and cystectomy

    Time frame: Baseline (T0), 40-60 days after surgery (T1), 12 months after surgery (T2)

  6. Ultrasound appearance of the ovary treated with APC

    Presence/absence of an ovarian cyst; cyst volume; cyst echogenicity (isoechoic, hyperechoic, hypoechoic, ground-glass appearance).

    Time frame: 40-60 days after surgery (T1)

  7. Ultrasound recurrence rate of endometrioma

    Presence/absence of an ovarian cyst with ground-glass content ≥ 10 mm

    Time frame: 12 months after surgery (T2)

  8. Histological appearance of the capsule of endometriomas treated with APC

    Maximum depth of necrosis; persistence of endometriotic foci

    Time frame: 40-60 days after surgery (T1), (during histological analysis of surgical specimens)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 21 months is below that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2026
First posted
Jun 24, 2026
StartActual
Sep 8, 2026was Jun 2026
Primary completionEst.
Jun 8, 2028
CompletionEst.
Dec 8, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
IRCCS Azienda Ospedaliero-Universitaria di Bologna is now Recruiting
Nov 12, 2026
Start date
Jun 8, 2026→Sep 8, 2026 (actual)
Nov 12, 2026
Title
Assessment of Ovarian Reserve in the Treatment of Ovarian Endometrioma With Cystectomy or Argon Plasma Coagulation: A Aandomized Clinical Trial
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    IRCCS Azienda Ospedaliero-Universitaria di Bologna is now Recruiting
    Start date Jun 8, 2026→Sep 8, 2026 (now actual)
    Title Assessment of Ovarian Reserve in the Treatment of Ovarian Endometrioma With Cystectomy or Argon Plasma Coagulation: A Aandomized Clinical Trial

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07666412
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Sep 8, 2026
Primary completion
Jun 8, 2028 (estimated)
Completion
Dec 8, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Diego Raimondo, MD
Contact
die.raimondo@gmail.com
+393290636618

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion